Soleus Capital Management, L.P. Vericel Corp Transaction History

Soleus Capital Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$29.0 - $38.37 $7.52 Million - $9.95 Million	-259,400 Reduced 79.46%	67,049 $2.52 Million
Q1 2023 May 15, 2023	SELL	$23.85 - $31.34 $13.9 Million - $18.3 Million	-582,548 Reduced 64.09%	326,449 $9.57 Million
Q4 2022 Feb 14, 2023	BUY	$17.65 - $27.37 $9.44 Million - $14.6 Million	534,997 Added 143.05%	908,997 $23.9 Million
Q3 2022 Nov 14, 2022	BUY	$22.62 - $32.54 $8.46 Million - $12.2 Million	374,000 New	374,000 $8.68 Million
Q1 2021 May 17, 2021	SELL	$30.93 - $59.48 $7.32 Million - $14.1 Million	-236,589 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$18.53 - $31.5 $2.16 Million - $3.67 Million	-116,417 Reduced 32.98%	236,589 $7.31 Million
Q3 2020 Nov 13, 2020	BUY	$14.68 - $19.12 $1.68 Million - $2.19 Million	114,474 Added 47.99%	353,006 $6.54 Million
Q2 2020 Aug 14, 2020	SELL	$8.5 - $15.82 $967,300 - $1.8 Million	-113,800 Reduced 32.3%	238,532 $3.3 Million
Q1 2020 May 15, 2020	BUY	$7.25 - $19.22 $1.22 Million - $3.24 Million	168,652 Added 91.82%	352,332 $3.23 Million
Q4 2019 Feb 14, 2020	BUY	$13.77 - $19.2 $2.53 Million - $3.53 Million	183,680 New	183,680 $3.2 Million

277

48.3M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.78B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.